Overview

Replimune develops cancer therapies that use engineered viruses (oncolytic immunotherapies) to attack tumors. These treatments selectively infect cancer cells, causing their destruction, and at the same time stimulate the immune system to recognize and fight tumors. By combining multiple methods of action, Replimune aims to boost the effectiveness of existing immune checkpoint inhibitors and create a stronger anti-tumor response. The company focuses on research, development, and clinical testing, and plans to earn revenue through partnerships, licensing, and eventual sales of approved therapies. Its goal is to deliver workable cancer treatments by validating safety and efficacy in clinical trials and bringing these therapies to patients with various cancers.

Significant Headcount Growth